Showing 3031-3040 of 7282 results for "".
- November is Hyperhidrosis Awareness Monthhttps://practicaldermatology.com/news/november-is-hyperhidrosis-awareness-month-1/2461411/November is Hyperhidrosis Awareness Month and the
- Monkeypox Update: Kids Aged 8 or Younger at High Risk for More Severe Monkeypoxhttps://practicaldermatology.com/news/monkey-pox-update-kids-aged-8-or-younger-at-high-risk-for-more-severe-monkeypox/2461409/Children aged 8 years or younger are at high risk for more severe monkeypox disease, reports The Pediatric Infectious Disease Journal. Young children would be a key target group for smallpox vaccination and other urgent measures if the outbreak widens, according to the review b
- EMA Accepts Filing of MAA for Almirall's Lebrikizumab in ADhttps://practicaldermatology.com/news/ema-accepts-filing-of-maa-for-almiralls-lebrikizumab-in-ad/2461408/The European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for Almirall’s lebrikizumab for the treatment of moderate to severe atopic dermatitis. Lebrikizumab is a novel, investigational, monoclonal antibod
- EWG: FDA Must Ban Oxybenzone in Sunscreen Now!https://practicaldermatology.com/news/ewg-fda-must-ban-oxybenzone-in-sunscreen-now/2461405/The U.S. Food and Drug Administration (FDA) should ban oxybenzone in sunscreens, according to researchers at the Environmental Working Group (EWG). For decades, sunscreen makers have used oxybenzone in their products, despite concerns about its health harms. In 2021, the FDA t
- Nevisense Improves Dermatologist’s Decision-making Beyond Dermoscopyhttps://practicaldermatology.com/news/nevisense-improves-dermatologists-decision-making-beyond-dermoscopy/2461403/SciBase’s Nevisense test provides benefit over standard of care visual and dermoscopic evaluation for biopsy decisions, according to a study in Melano
- EltaMD Honored in Fast Company Magazine’s 2022 “Brands That Matter” Listhttps://practicaldermatology.com/news/eltamd-honored-in-fast-company-magazines-2022-brands-that-matter-list/2461402/EltaMD has been named to Fast Company’s “Brands that Matter” list for its memorable campaign to increase awareness of skin cancer and how to prevent it. The list honors companies and nonprofits that have had an undeniable impact on business and culture. Skin
- Potential Hair Growth Breakthrough: Researchers Grow Mature Hair Follicles in Labhttps://practicaldermatology.com/news/potential-hair-growth-breakthrough-researchers-grow-mature-hair-follicles-in-lab/2461398/Japanese researchers have successfully grown hair follicles in the lab. The team created a system that produces fully mature hair follicles as well as hair as long as 3 millimeters after a few weeks' growth. The in vitro hair follicle model adds to the understanding of ha
- European Commission Approves LEO Pharma’s Adtralza (tralokinumab) for the Treatment of Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/european-commission-approves-leo-pharmas-adtralza-tralokinumab-for-the-treatment-of-moderate-to-severe-ad-in-adolescents/2461394/The European Commission (EC)e xtended the marketing authorization for LEO Pharma’s Adtralz (tralokinumab) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. “Safety is a priority when s
- Phase 3 Data: Opdivo Reduced Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/phase-3-data-opdivo-reduced-risk-of-recurrence-or-death-by-58-versus-placebo-in-patients-with-completely-resected-stage-iib-or-iic-melanoma/2461391/Bristol Myers Squibb shared results from the Phase 3 CheckMate -76K trial, in which Opdivo (nivolumab) as an adjuvant therapy demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival (RFS) versus placebo in patients with completely resected stage IIB
- Skin Microbiome Linked to GVHD Following Stem Cell Transplant in Leukemiahttps://practicaldermatology.com/news/skin-microbiome-linked-to-gvhd-following-stem-cell-transplant-in-leukemia/2461385/Organ damage occurs in up to 70 percent of patients in the first few months following stem cell transplant, but the precise reasons for this potentially life-threatening reaction haven’t been fully understood. Now, researchers led by Georg Stary from the Department of Dermatology at MedUni